Top Wealth Group (TWG) disclosed late Friday a "positive" outlook for the financial year ending Dec. 31, anticipating net profits of not less than $4 million, rebounding from a $2 million loss a year ago.

Shares of the company more than doubled as intraday trading volume catapulted to over 16.5 million from a daily average of about 249,000.

Wave Life Sciences (WVE) said Monday that interim data from its phase 1 trial of WVE-007, an obesity treatment, showed improvements in body composition.

The weight loss was similar to GLP-1, but without muscle loss, the company added.

Shares of the company soared 140% as intraday trading volume surged to over 119 million from a daily average of roughly 2.6 million.

Structure Therapeutics (GPCR) disclosed on Monday that its obesity drug candidate aleniglipron achieved statistical significance in the phase 2b trial's primary and key secondary endpoints.

Shares of the company surged 99% as intraday trading volume climbed to more than 16.1 million from a daily average of about 1.1 million.

Price: 19.63, Change: +13.62, Percent Change: +226.62